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Essentials
• Low anticoagulation intensity reduces bleeding but increases thrombosis during warfarin therapy. • Elevated D-dimer level is associated with increased thrombosis events.
• D-dimer can be used to find potential thrombosis in those receiving low intensity therapy.
• D-dimer-guided therapy may be the optimal strategy for those with mechanical heart valve replacement.
Summary. Background: Controversies remain regarding the optimal anticoagulation intensity for Chinese patients after mechanical heart valve replacement despite guidelines having recommended a standard anticoagulation intensity. Objectives: To investigate whether D-dimer could be used to determine the optimal anticoagulation intensity in Chinese patients after mechanical heart valve replacement. Patients/Methods: This was a prospective, randomized controlled clinical study. A total of 748 patients following mechanical heart valve replacement in Wuhan Asia Heart Hospital were randomized to three groups at a ratio of 1 : 1 : 1. Patients in two control groups received warfarin therapy based on constant standard intensity (international normalized ratio [INR], 2.5-3.5; n = 250) and low intensity (INR, 1.8-2.6; n = 248), respectively. In the experimental group (n = 250), warfarin therapy was initiated at low intensity, then those with elevated D-dimer levels were adjusted to standard intensity. All patients were followed-up for 24 months until the occurrence of endpoints, including bleeding events, thrombotic events and all-cause mortality. Results: A total of 718 patients were included in the analysis. Fifty-three events occurred during follow-up.
There was less hemorrhage (3/240 vs. 16/241; hazard ratio [HR] , 0.18; 95% confidence interval [CI] , 0.07-0.45) and all-cause mortality (4/240 vs. 12/241; HR, 0.33; 95% CI, 0.12-0.87) observed in the D-dimer-guided group than in the standard-intensity group. A lower incidence of thrombotic events was also observed in the D-dimer-guided group when compared with the low-intensity group (5/ 240 vs. 14/237; HR, 0.35; 95% CI, 0.14-0.85). Overall, the total events were less in the D-dimer-guided group
Introduction
Mechanical heart valve replacement (MHVR) entails a lifetime of oral anticoagulation to mitigate thromboembolism. A vitamin K antagonist (VKA) remains an anticoagulant of choice for post-MHVR patients. A guideline recommends a standard anticoagulation intensity with international normalized ratio (INR) ranging from 2.5 to 3.5 for patients receiving mitral valve replacement (MVR) or double valve replacement (DVR, mechanical heart valves in both the aortic and mitral position) [1] . Nevertheless, controversies remain concerning the optimal anticoagulation intensity for Chinese patients on VKA therapy because several studies reported that Chinese patients receiving anticoagulation therapy at high intensity had a higher frequency of bleeding than their western counterparts [2, 3] . Therefore, low intensity (INR range, 1.8-2.6) was recommended for Chinese patients [2, [4] [5] [6] on VKA to minimize the risk of bleeding, although an increased rate of thrombosis was observed [7] . D-dimer, a product of cross-linked fibrin degradation, is only produced when both the blood coagulation and fibrinolytic pathways are concomitantly activated [8] . Elevated D-dimer levels are highly correlated with adverse clinical outcomes, including thrombotic or cardiovascular events and other severe conditions [8, 9] , which cover most complications following MHVR.
In view of the aforementioned findings, we are led to hypothesize that elevated D-dimer levels could be used to identify inadequately anticoagulated patients, thereby lowering adverse outcomes in Chinese patients on VKA therapy after MHVR. In this study, we conducted a prospective randomized controlled trial in Chinese patients receiving VKA therapy after MHVR, with an attempt to use D-dimer as an indicator for optimizing oral anticoagulation intensity.
Patients/Methods
The study was a prospective, single-center, parallel-group, randomized controlled trial conducted in Wuhan, China. The study compared the incidences of adverse outcomes among patients who received D-dimer-guided VKA therapy and those on unadjusted therapies at standard intensity and low intensity. No changes were made in protocol design, eligibility criteria or outcome evaluation once the trial started. The protocol was conducted in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. Ethical approval of this study was obtained from the Wuhan Asia Heart Hospital ethical committee (2013-P-002). The protocol was also registered at the registry of clinical trials (ClinicalTrials.gov; NCT01996657) before commencing recruitment. All enrolled patients provided written informed consent.
Participants and randomization
Participants were aged from 18 to 75 years and had received MVR or DVR surgery in Wuhan Asia Heart Hospital from January 2013 to May 2014. All patients had mechanical valves for valve replacement. The diagnosis was established by an expert panel. The necessity for surgical management was decided by attending surgeons on the basis of patients' condition at admission. VKA therapy began after surgery. Patients who had suffered from recent (within 3 months) myocardial infarction, ischemic stroke, deep vein thrombosis, cerebral hemorrhages or other serious diseases, or those who had difficulty in compliance or were unavailable for followup, were excluded.
Patients were randomized into each group at a ratio of 1 : 1 : 1. We used a random number generator for randomization when their surgery plans were decided. Patients were allocated to their corresponding groups before VKA therapy started. Patients were blind to the recruitment process, but were informed of the treatment during follow-up.
Patients' involvement
No patients were involved in the design of our study or development of the research questions and outcome measures. No patients had any involvement in the recruitment to and conduct of the study. No patients took part in the assessment of the intervention. There were no plans to involve patients in the dissemination of the study results.
Laboratory assay and intervention
The international normalized ratio was employed for monitoring anticoagulation intensity, and it was measured every 1-2 month(s) during the follow-up. D-dimer baseline was set up at 3-6 months upon inception of VKA therapy. The INR and D-dimer were determined on an automatic analyzer (ACL-TOP 700, Instrumentation Laboratory, Bedford, MA, USA). The INR was measured by HemosIL Ò RecombiPlasTin2G reagent (international sensitivity index, 0.98-1.01; Instrumentation Laboratory). Quality control was maintained by using a commercial product (Lyphochek Ò , Bio-rad, Irvine, CA, USA). Interand intra-day variability coefficients were 1.89% and 2.15%. D-dimer level was determined by utilizing a latexenhanced photometric immunoassay (HemosIL Ò D-dimer HS 500, Instrumentation Laboratory). Quality control was performed by using an internal laboratory standard in-house plasma pool. Inter-and intra-day variability coefficients were 3.36% and 4.57%. The D-dimer result was expressed in lg L À1 FEU (Fibrinogen Equivalent Unit). All measurements were performed in an onsite laboratory within 2 h of blood sampling. A uniform cut-off value (500 lg L À1 ) was used for D-dimer in patients under 50 years. An age-adjusted cut-off value was used for D-dimer in patients who were 50 years or older (ageadjusted cut-off = [age, years] 9 10 lg L À1 ) [10] .
In this study, two control groups and one investigational group were set up ( Fig. 1) . Patients in control groups received VKA therapy constantly at standard intensity (SIT; INR, 2.5-3.5) and low intensity (LIT; INR, 1.8-2.6), respectively. Patients in the investigational group (D-dimer-guided therapy, DGT) were initially given VKA therapy at low intensity (INR, 1.8-2.6). The intensity was adjusted to the standard one (INR, 2.5-3.5) as soon as the D-dimer level was found to be elevated during the first establishment of D-dimer. After adjustment, the D-dimer test was repeated 3 months later. Patients who did not experience D-dimer elevation in the investigational group remained on the original anticoagulation regimen (INR, 1.8-2.6).
Follow-up and endpoints
All patients were followed-up for 24 months unless the endpoints occurred. The endpoints were defined according to guidelines [11, 12] , including thrombotic or major bleeding events and all-cause mortality. Specifically, the thrombotic events covered valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism and myocardial infarction [11] . The major bleeding events involved hemorrhages that were intracranial, retroperitoneal, or were associated with a fall in hemoglobin of at least 20 g L À1 , or required transfusion of two or more units of whole blood or red cells [12] .
Sample size
Our study aimed to assess whether D-dimer could be used to optimize VKA therapy in Chinese patients after MHVR. We carried out the study in three groups at a ratio of 1 : 1 : 1. Based on previously reported incidences of bleeding and thrombosis [3, 13] , we determined the sample size of the study by using an online sample size estimation tool (http://powerandsamplesize.com/Calcu lators). According to our calculation, a total of 220 patients in each group would provide a one-sided statistical power of 0.90 and two-sided one of 0.85. Therefore, we recruited more than 700 patients for our study, with over 220 patients in each group.
Statistical analysis
We compared the rate of events among each group during follow-up. Continuous variables were expressed as mean AE standard deviation. Categorical variables were presented as absolute numbers or percentages. Differences among groups were assessed by t-test or ANOVA analysis for continuous variables and chi-squared test for categorical variables. Kaplan-Meier survival curves were plotted to estimate the cumulative incidences of major endpoints. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the Cox proportional-hazards model. The data were analyzed by employing SPSS (SPSS Statistics
Results

Patients included in the analysis
A total of 772 patients were initially screened at Wuhan Asia Heart Hospital before the study began. After excluding 24 patients who were not able to fully participate in the study, 748 patients were enrolled and randomized to three groups equally as described in the Methods section. Enrollment and flow chart of the study are shown in Fig. 1 . Thirty patients were removed from the study: five died or were readmitted before D-dimer assay was performed; 11 were lost during follow-up; 14 failed to reach target INR (mean INR was out of target range). Overall, 718 patients completed the study.
Baseline clinical characteristics
Listed in Table 1 are the basic clinical characteristics of the patients, including age and gender, valve position, diabetes, hypertension, BMI and other related medical histories. No differences in these items apart from INR and D-dimer levels were seen among the three groups. Elevated D-dimer level was more frequent in the LIT and DGT groups than in the SIT group (38 in LIT, 37 in DGT vs. 18 in SIT, P = 0.005).
Clinical outcomes among three groups
Clinical outcomes are listed in Table 2 . In total, 53 endpoint events were observed during follow-up. Of 23 patients who had bleeding events, 16 received VKA therapy at standard intensity. Among 24 patients who experienced thrombotic events, 14 were in the LIT group. Six patients died from heart failure and other non-cardiac causes. Compared with the SIT group, the LIT group had substantially fewer bleeding events (HR, 0.25; 95% CI, 0.11-0.61; P = 0.0077; Fig. 2A ). All-cause mortality in the LIT group also showed a decreasing trend (HR, 0.42; 95% CI, 0.16-1.09; P = 0.093. Fig. 2C ). Nevertheless, more thrombotic events were observed in the LIT group (HR, 2.82; 95% CI, 1.15-6.93; P = 0.037; Fig. 2B ). Finally, VKA therapy at low intensity did not have significant advantages over SIT in decreasing the incidence of total events (HR, 0.84; 95% CI, 0.47-1.52; P = 0.56; Fig. 2D ).
On the other hand, compared with the SIT group, the DGT group had significantly lower incidences of bleeding events (HR, 0.18; 95% CI, 0.07-0.45; P = 0.0023; Fig. 2A ) and all-cause mortality (HR, 0.33; 95% CI, 0.12-0.87; P = 0.040; Fig. 2C ) without concomitant increase in thrombotic incidents (HR, 0.97; 95% CI, 0.28-3.37; P = 0.97; Fig. 2B ). In the DGT group, starting the VKA therapy at a low intensity resulted in a low incidence of bleeding, as it did in the LIT group (HR, 0.72; 95% CI, 0.16-3.18; P = 0.67; Fig. 2A ). No differences were found in all-cause mortality between the DGT group and the LIT group (HR, 0.77; 95% CI, 0.21-2.86; 
D-dimer levels in the DGT group
In the DGT group, 37 patients initially had elevated D-dimer levels after receiving low-intensity anticoagulation therapy. Their target INR range rose from 1.8-2.6 to 2.5-3.5 after warfarin dosage was increased. After adjustment, the average INR of those patients increased from 2.03 to 2.93. The D-dimer test was repeated at 3 months after dose adjustment. Patients' D-dimer levels responded differently to the dose adjustment. In 21 patients, the level decreased to normal after the adjustment, whereas in the other 16, the level remained abnormal. Notably, no adverse events happened in patients whose D-dimer level dropped to normal, but two events (one thrombosis and one cancer-related death) took place among the 16 patients whose D-dimer remained abnormal.
Discussion
Our study demonstrated that D-dimer-guided adjustment of VKA therapy significantly lowered adverse clinical outcomes in Chinese patients after MHVR when compared with anticoagulation therapy constantly at standard intensity (INR, 2.5-3.5) and low intensity (INR,1.8-2.6). Additionally, events analysis showed that more frequent bleeding events and higher mortality were seen in patients receiving VKA therapy at standard intensity, which further confirmed that standard anticoagulation treatments based on international guidelines are not suitable for Chinese patients. We also observed that VKA therapy at low intensity, as suggested by a few researchers, did reduce the bleeding events in Chinese patients after MHVR but at a cost of an increased risk of thrombosis. Over the past years, research efforts have been directed at optimizing VKA therapy. Researchers tried to reduce the overall risk for VKA patients by finding optimal anticoagulation intensity [14] [15] [16] . The therapeutic INR ranges generated from those studies are recommended by the contemporary practice guidelines [1, 17] . However, all the previous clinical studies were based on strategies at constant intensity, namely, a consistent target INR range was used for VKA patients during their lifetime of anticoagulation therapy. A great number of patients are treated to reach the same target intensity irrespective of their potential biological variations. Although guidelines have suggested different therapeutic target INR ranges for different diseases, some patients on VKA therapy at consistent intensity are at a high risk of developing either bleeding or thrombosis. Because of the polymorphism of the hemostatic gene, and differences in factor levels, endothelial markers, platelet reactivity and thrombolytic status, Asian patients might be more subject to bleeding than their Caucasian counterparts [18] [19] [20] .
Shen and colleagues showed that Asian patients had a high incidence of bleeding when their anticoagulation strategy was based on standard intensity [21] . In view of this, Dong et al. suggested a lower intensity that would reduce bleeding events in Asian patients [4, 6] . However, VKA therapy at constant intensity for Asian patients, even at a lower level, is not a one-for-all solution to the problem. Asian patients on low-intensity VKA therapy SIT, standard-intensity therapy; LIT, low-intensity therapy; DGT, D-dimer-guided therapy.
were reportedly still at high risk of thrombosis [7] , which was also confirmed by our findings. Moreover, those risks cannot be identified by INR test alone. Realizing the inadequacy of using INR alone, we employed D-dimer as a complementary marker to INR to find the best anticoagulation intensity for inadequately anticoagulated Chinese patients on post-MHVR VKA therapy.
The value of D-dimer in patients on VKA therapy in terms of prognosis assessment has been described in previous studies. Giansante and associates reported a 2-year follow-up study in 132 patients after MHVR [22] . In their observational study, patients with elevated D-dimer levels had a 5-fold higher risk of having vascular thromboembolic events. Multiple studies demonstrated that AF patients with abnormal D-dimer levels during VKA therapy tended to have more adverse clinical outcomes [9, 23, 24] . Nevertheless, these studies didn't offer the solutions to minimize D-dimer elevation-related events. Lip et al. reported that D-dimer level could be reduced by introducing warfarin [25] , which prompted us to assume that increasing anticoagulation intensity might reduce Ddimer elevation-related events in post-MHVR patients. In fact, our findings strongly supported the assumption. Additionally, there were still two events that happened to those 16 patients whose D-dimer levels remained abnormal after warfarin dose adjustment, whereas no events happened to the 21 patients whose D-dimer decreased to normal during the follow-up period. Switching to higher intensity for those whose D-dimer levels remained abnormal may offer more clinical benefits, but further studies are needed because the number of events was very limited. Our study has several strengths. First and foremost, our study introduced D-dimer assay, one of the most common coagulation tests, as a complementary marker to INR during VKA therapy. Our study demonstrated that D-dimer level could indicate the status of anticoagulation, thus helping clinicians adjust anticoagulation intensity to reduce unfavorable outcomes. Easy accessibility and wide acceptance of D-dimer assay render its application clinically feasible. Second, our evaluation covered most anticoagulation intensities by carrying out a three-arm, randomized controlled study. Two control groups were designed to cover the two most common anticoagulation strategies used in China (i.e. standard intensity [INR range, 2.5-3.5] and low intensity [INR range, 1.8-2.6] regimens). An experimental group was set up to test the advantages of the D-dimer-guided treatment over the standard and low-intensity therapies, and our results revealed that the D-dimer-guided therapy could substantially eliminate the thrombosis and bleeding events. Third, great effort was made to achieve quality control of anticoagulation, including monitoring INR once a month. Owing to the strict high quality across the entire study process, our results should be objective and reliable.
This study also has several limitations. First, our study might have selection bias because it was a single-center study, even if it had sufficient power to detect the significant differences among groups in main outcomes. Despite our efforts to include all qualified patients, some patients refused to participate in the study because of some restraints in revisiting our center as required. Second, our follow-up time was relatively short. Thus, long-term outcomes of the patients receiving D-dimer-guided therapy are not known. Third, given the fact that D-dimer assay has well-accepted reproducibility [26] , we measured the D-dimer levels for all patients at the early stage of the study. Because we didn't dynamically monitor the Ddimer levels, the D-dimer level at the time of events was unknown. What is more, we didn't know whether the Ddimer levels that had been originally normal became abnormal during follow-up. Therefore, dynamic measurement of D-dimer will reveal more information. Fourth, the LIT group showed a decreasing trend but no significant difference in all-cause mortality (15 vs. 5; P = 0.093; Fig. 2C ) compared with the SIT group. The statistical significance might be observed if the sample size is large enough or follow-up period is long enough. Fifth, the fully adjusted model analysis for HRs was not performed, given the low number of events.
Further large-sample and multicenter studies are warranted to confirm our findings. Whether D-dimer-guided adjustment of VKA therapy can be applied to western patients or patients with other diseases, such as AF, and so on, needs to be further investigated.
Conclusions
Our study found that VKA therapy at low intensity reduces bleeding events in Chinese patients after MHVR, but at a cost of an elevated risk of thrombosis. Furthermore, D-dimer might serve as an indicator to determine the optimal anticoagulation intensity for Chinese patients after MHVR.
